BCL2 and acute myeloid leukemia: For all the above reasons, numerous therapies and ongoing clinical trials for AML treatment are concentrating on mitochondrial molecules [10] and have shown potential, including Venetoclax, an efficient Bcl-2 inhibitor, which acts on mitochondrial cristae structure and promotes mitochondrial apoptotic pathway [14] and other drugs directed against specific components of the electron transport chain (ETC) like Complexes I and III [15,16,17,18].